Tilt Investment Management Holdings PBC Takes $369,000 Position in Zoetis Inc. (NYSE:ZTS)

Tilt Investment Management Holdings PBC purchased a new position in Zoetis Inc. (NYSE:ZTS) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,872 shares of the company’s stock, valued at approximately $369,000.

A number of other large investors also recently modified their holdings of ZTS. Blue Bell Private Wealth Management LLC boosted its holdings in Zoetis by 222.5% in the 4th quarter. Blue Bell Private Wealth Management LLC now owns 129 shares of the company’s stock valued at $25,000 after purchasing an additional 89 shares during the period. Nelson Van Denburg & Campbell Wealth Management Group LLC raised its position in shares of Zoetis by 430.8% in the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 138 shares of the company’s stock worth $26,000 after buying an additional 112 shares in the last quarter. VitalStone Financial LLC bought a new stake in Zoetis during the first quarter valued at $37,000. Evermay Wealth Management LLC boosted its stake in Zoetis by 439.3% during the first quarter. Evermay Wealth Management LLC now owns 151 shares of the company’s stock valued at $25,000 after buying an additional 123 shares during the period. Finally, Worth Asset Management LLC purchased a new position in Zoetis during the first quarter worth about $26,000. 92.80% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have weighed in on ZTS. Barclays raised their price target on Zoetis from $255.00 to $260.00 and gave the company an “overweight” rating in a report on Wednesday, February 14th. The Goldman Sachs Group raised their target price on shares of Zoetis from $190.00 to $226.00 and gave the company a “buy” rating in a research note on Wednesday, January 17th. Piper Sandler reissued an “overweight” rating and issued a $195.00 price target (down previously from $220.00) on shares of Zoetis in a research note on Tuesday. StockNews.com cut shares of Zoetis from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 20th. Finally, Stifel Nicolaus cut their target price on shares of Zoetis from $215.00 to $195.00 and set a “buy” rating for the company in a research report on Tuesday, April 2nd. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Zoetis presently has an average rating of “Buy” and a consensus price target of $221.75.

Insider Buying and Selling at Zoetis

In other news, EVP Roxanne Lagano sold 363 shares of the firm’s stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $197.74, for a total value of $71,779.62. Following the transaction, the executive vice president now owns 20,417 shares in the company, valued at $4,037,257.58. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.12% of the company’s stock.

Zoetis Trading Up 0.6 %

Shares of ZTS stock traded up $0.96 on Thursday, hitting $152.47. 3,367,593 shares of the company’s stock traded hands, compared to its average volume of 2,970,040. The stock has a market capitalization of $69.73 billion, a price-to-earnings ratio of 30.15, a P/E/G ratio of 2.34 and a beta of 0.85. The company’s fifty day simple moving average is $177.35 and its 200 day simple moving average is $180.39. Zoetis Inc. has a one year low of $148.48 and a one year high of $201.92. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.00 and a current ratio of 3.36.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Tuesday, February 13th. The company reported $1.24 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.32 by ($0.08). The business had revenue of $2.21 billion for the quarter, compared to analysts’ expectations of $2.19 billion. Zoetis had a net margin of 27.43% and a return on equity of 51.25%. The business’s quarterly revenue was up 8.5% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.15 earnings per share. Equities analysts forecast that Zoetis Inc. will post 5.79 EPS for the current year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Friday, April 19th will be paid a $0.432 dividend. The ex-dividend date is Thursday, April 18th. This represents a $1.73 dividend on an annualized basis and a yield of 1.13%. Zoetis’s dividend payout ratio (DPR) is currently 34.12%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.